Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blind, Placebo-Controlled, Parallel Group Design Trial of the Selective D3 Antagonist, GSK598809, Added to CBT (Cognitive Behavioral Therapy) and NRT (Nicotine Replacement Therapy) for Smoking Cessation and Prevention of Very Early Relapse to Smoking

Next Previous
Trial Profile

A Double-Blind, Placebo-Controlled, Parallel Group Design Trial of the Selective D3 Antagonist, GSK598809, Added to CBT (Cognitive Behavioral Therapy) and NRT (Nicotine Replacement Therapy) for Smoking Cessation and Prevention of Very Early Relapse to Smoking

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 26 Jun 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GSK 598809 (Primary)
  • Indications Smoking withdrawal
  • Focus Therapeutic Use

Most Recent Events

  • 16 May 2014 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top